Why Interest Rate Rises Won’t Hurt High-Yield Shares

High-yield shares such as GlaxoSmithKline plc (LON: GSK) and Imperial Tobacco PLC (LON: IMT) are unlikely to be hit hard.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Graph showing the FTSE 100 index and FTSE 100 dividend points from October 1999 to October 2013Bank of England Governor, Mark Carney, surprised many investors with his Mansion House speech, where he hinted that interest rates could go up as soon as this year. Indeed, many investors had expected him to wait until after the General Election in 2015 before increasing rates from their historic lows of 0.5%.

In terms of the effect on the stock market, a rise is usually not good news. That’s because (in theory) there is less incentive to invest versus save and it could be argued that high-dividend-paying shares such as GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and Imperial Tobacco (LSE: IMT) could be hit harder as demand for a higher yield declines. However, that may not hold true over the next few years. Here’s why.

High Yields Will Still Be High Yields

Partly as a result of interest rate rises starting from such a low base (a historical low of 0.5%), they will have to increase by a very high multiple before they begin to look attractive to investors. In other words, a 1% rate of interest may be twice as attractive as 0.5%, but is still below inflation and therefore very unattractive. As such, even if interest rates are doubled, trebled or quadrupled, they may not cause a vast number of investors to suddenly sell shares in GlaxoSmithKline and Imperial Tobacco and instead open savings accounts.

Furthermore, the rate at which interest rates are likely to rise may be somewhat pedestrian. In other words, the credit crunch is a very recent memory for the Bank of England and it may be unwilling to take a gamble on choking the UK’s current economic recovery. As a result, interest rates are unlikely to swiftly move the 5%+ level that was in place prior to the credit crunch, meaning high yielding shares are likely to remain attractive over the medium term.

Two High-Yielding Shares With Strong Prospects

When it comes to high yields, they don’t come much higher at present than GlaxoSmithKline and Imperial Tobacco. Both companies are in the top 15 highest-yielding FTSE 100 companies and currently offer yields of 4.8% and 4.4% respectively. Furthermore, dividends are well covered and are set to increase at an attractive pace in the coming years, thereby helping investors in the two companies to stay one step ahead of interest rate rises (whenever they may eventually come).

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is Avon Protection the best stock to buy in the FTSE All-Share index right now?

Here’s a stock I’m holding for recovery and growth from the FTSE All-Share index. Can it be crowned as the…

Read more »

Investing Articles

Down 8.5% this month, is the Aviva share price too attractive to ignore?

It’s time to look into Aviva and the insurance sector while the share price is pulling back from year-to-date highs.

Read more »

Investing Articles

Here’s where I see Vodafone’s share price ending 2024

Valued at just twice its earnings, is the Vodafone share price a bargain or value trap? Our writer explores where…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

The Darktrace share price jumped 20% today. Here’s why!

After the Darktrace share price leapt by a fifth in early trading, our writer explains why -- and what it…

Read more »

Dividend Shares

850 shares in this dividend giant could make me £1.1k in passive income

Jon Smith flags up one dividend stock for passive income that has outperformed its sector over the course of the…

Read more »

Investing Articles

Unilever shares are flying! Time to buy at a 21% ‘discount’?

Unilever shares have been racing higher this week after a one-two punch of news from the company. Here’s whether I…

Read more »

artificial intelligence investing algorithms
Market Movers

The Microsoft share price surges after results. Is this the best AI stock to buy?

Jon Smith flags up the jump in the Microsoft share price after the latest results showed strong demand for AI…

Read more »

Google office headquarters
Investing Articles

A dividend announcement sends the Alphabet share price soaring. Here’s what investors need to know

As the Alphabet share price surges on the announcement of a dividend, Stephen Wright outlines what investors should really be…

Read more »